Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
2.070
+0.160 (8.38%)
At close: Jun 3, 2025, 4:00 PM
2.100
+0.030 (1.45%)
After-hours: Jun 3, 2025, 7:56 PM EDT
Autolus Therapeutics Employees
As of December 31, 2024, Autolus Therapeutics had 650 total employees, including 647 full-time and 3 part-time employees. The number of employees increased by 179 or 38.00% compared to the previous year.
Employees
650
Change (1Y)
179
Growth (1Y)
38.00%
Revenue / Employee
$13,863
Profits / Employee
-$366,358
Market Cap
550.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AUTL News
- 5 days ago - Autolus Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) - GlobeNewsWire
- 14 days ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 20 days ago - Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress - GlobeNewsWire
- 23 days ago - Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event - GlobeNewsWire